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Results. Median age of the patients was 71 years (range 58–81), median pre-treatment PSA was 9.6ng/ml (3.3–88.9). Eighty-three
percent of the patients were Gleason ≥7. Forty seven percent had ≥50 of cores involved. Forty-eight percent of patient’s PSA was
≥10ng/ml. Pre-MRI staging was T1 in 70% of the patients, T2 in 26% and T3 in 4%. Of the 70 patients staged by MRI, 93% were
upstaged from the digital rectal examination-based clinical stage; 47% of cT1-T2 patients were upstaged to cT3. This upstaging
changed the risk group in 31% of the patients while using the NCCN classiﬁcation and in 44% when the D’Amico classiﬁcation
was used. The treatment recommendation was modiﬁed in 23% and 44% of the patients using the NCCN and the D’Amico
classiﬁcation respectively.
Conclusion. StagingMRI impacts in the assessment of the local staging, risk group classiﬁcation and treatment decision in interme-
diate and high risk patients undergoing HDR brachytherapy and EBRT. If possible, multiparametric MRI should be recommended
for staging purposes in all patients undergoing radical treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.492
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Purpose. IMRT using Simultaneous Integrated Boost (SIB) in patients with high-risk prostate cancer.
Material and methods. 137 patients diagnosed of high risk prostate cancer (HRPC) according to NCCN criteria, were treated during
the period from July 2008 through December 2011, with mean of follow up of 35 months (5–88). The median age 68 years (45–83).
TheT stage≥N2cwas 50%of patients, Gleason≥8was in 56%of cases,more frequent 4+4 andmore than 60%hadPSA levels above
10ng/ml. 34% with perineural invasion. The planning by computed tomography (CT)-scan was performed with immobilization
of the lower extremities. SIB treatment plans for intensity-modulated RT (IMRT) was “step and shoot”. Delimiting the following
volumes: – PTV1 lymph node chains – PTV2 seminal vesicles – PTV3 prostate target, seminal vesicles and prostate with cT3b.
– Organs at risk: Bowel, bladder, rectum and femoral heads. – A total dose of 54.12Gy at 1.64Gy was given to PTV1. 59.40Gy
at 1.80Gy/fraction to PTV2 and 74.25–75.90Gy in 33 daily fractions to PTV3. The most of patients received adjuvant hormonal
treatment for 2–3 years.
Results. In HRPC for improve progression free survival is advisable to irradiate pelvical nodes, at the expense of carry the risk of
increasing adverse effect rates in particular for small bowel. That is why is necessary to use more precise technique than 3D
conventional treatment. We report the results of 137 patients treated by IMRT (SIB) Dosimetric results: 80% of patients had V70 of
rectum less than10%. The mean of the maximal dose of rectum was 76.99Gy (73.97–82.80Gy). Small bowel: 60% of all cases had
V30 less than 40%. Bladder: 90% of patients V60<40%. Toxicity results: According to RTOG criteria. The treatment was stopped
in 2 patients for acute cystitis and proctitis GII. Acute rectitis GI-II observed in 20%. Acute enteritis 90% G0. Chronic toxicity: was
around 20% of cystitis GI and only 1 patient suffered proctitis GIII. With a follow up of 4 years is early to observe the evolution
in terms of survival outcome and biochemical control owing to the natural history of prostate cancer and adjuvant androgen
suppression therapy.
Conclusion.The IMRT-boost protocol has integratedwith verywell tolerance of patients, reducing signiﬁcantly the enteritis–rectitis
high grade acute and chronic toxicity. It is necessary more time to see results in terms of locoregional and biochemical control.
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Introduction. In severe cases refractory to medical treatment, APC appears to be the preferred alternative to control persistent
rectal bleeding of patients with chronic radiation proctitis. Only 6 articles including series with more than 30 patients have been
published to date.
Objectives. The aim of this study was to assess the efﬁcacy and toxicity of APC in the management of bleeding radiation-induced
proctitis.
Methods and materials. Data from 30 patients were treated with APC due to chronic radiation proctitis, were reviewed retrospec-
tively. All cases had prostate cancer and 9 of them (30%) underwent previous radical prostatectomy. The median dose of External
Beam Radiation Therapy (EBRT) conformal 3D delivered was 74Gy (range 46–76). Median rectal D1cc and D2cc was 72.5 and
72.4Gy respectively. Median rectal V70, V60 and V40 was 12, 39,5 and 80%. Indications for treatment with APC were anemia and
persistent bleeding despite medical treatment. Argon gas ﬂow was set at 1.8 l/min with an electrical power setting of 40W.
